These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing, reported early 2004-000081-13 A randomized, controlled, open-label, multi-center, parallel group study to demonstrate efficacy and safety of RO0503821 when administered with pre-filled syringes for the maintenance treatment of ane... not-yet-due
Other 2004-000231-29 Safety and pharmacokinetics of valganciclovir syrup formulation in paediatric solid organ transplant recipients not-yet-due
Ongoing, reported early 2004-000282-35 A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line treat... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-000315-26 First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program. 2007-10-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-000564-28 AN EXPANDED ACCESS PROGRAM OF TARCEVA (ERLOTINIB) IN PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER 2008-09-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-000596-34 A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve... 2006-09-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-000715-26 A randomised, Three Arm Multinational Phase III Study to investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leuco... 2012-06-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-000752-17 Phase II study of Herceptin® alone or in combination with a taxane, as a first-line treatment for patients with metastatic breast cancer, who have relapsed after receiving Herceptin® in the adjuvant s... 2012-06-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-000864-29 A randomized, double-blind multicenter 2-stage phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recur... 2016-06-30 bad-data
Reported results 2004-000983-29 Effectiveness of a once weekly subcutaneous epoetin beta treatment in hemodialysis patients. 2006-11-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-001224-21 A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral (ARV) to enfuvirtide (ENF) and to assess resolution or improvement of ARV toxi... 2006-10-23 bad-data
Ongoing, reported early 2004-001298-24 An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis not-yet-due
Reported results 2004-001548-60 Double-blind, partially randomized, parallel group, multicenter study to assess the efficacy and safety of 100 mg and 150 mg monthly oral ibandronate in women with postmenopausal osteoporosis having c... 2008-05-20 due-trials
Ongoing 2004-001685-40 An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leu... not-yet-due
Listed as ongoing, but also has a completion date 2004-001688-23 A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerability of 12 months of once daily treatment with 1 mg of RO3300074 in patients with symptomatic emphy... 2008-05-27 bad-data
Not reported 2004-001718-15 An open-label, multicenter protocol providing pegylated interferon alfa 2-a PEGASYS as monotherapy or in combination with ribavirin COPEGUS for patients with chronic hepatitis C who have partecipat... 2011-09-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-001854-10 Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in pa... 2007-02-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-001855-12 Randomized, two arm, placebo controlled study to compare the efficacy of intravenous loading doses followed by maintenance treatment with intravenous ibandronic acid versus zoledronic acid in patients... 2007-02-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002032-26 An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia 2009-12-22 bad-data
Ongoing, reported early 2004-002093-30 Extension protocol for patients with Chronic Myelogenous Leukemia (CML), Malignant Melanoma (MM) or Renal Cell Carcinoma (RCC) that have responded to treatment with Pegylated-interferon α-2a (PEG-IFN)... not-yet-due
Ongoing, reported early 2004-002131-12 Evaluation of efficacy and safety of ibandronate as treatment of metastatic bone pain in patients with different tumor types. A randomised phase II study not-yet-due
Other 2004-002132-26 A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moderate... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-002255-14 Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150 mg ibandronate with once-weekly oral administrat... 2007-01-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002570-32 Open label, parallel group, multicenter study of two intravenious ibandronate regimens (2 mg every 2 months and 3 mg every 3 months) in women with postmenopausal osteoporosis who completed trial BM165... 2010-11-27 bad-data
Completed, but no date, and reported results 2004-002733-39 FC + rituximab followed by rituximab maintenance treatment in patients with advanced untreated Indolent B-cell Non follicular Lymphomas: phase II study. bad-data
Listed as ongoing, but also has a completion date 2004-002787-15 Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FC-R) versus chemotherapy with Fludarabine and Cyclophosophamide (FC) alone in patients with previously... 2011-12-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002798-21 A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalizatio... 2006-07-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002854-78 A randomised, double blind, placebo controlled, multicentre phase III trial to evaluate the efficacy and safety of adding bevacizumab to gemcitabine and erlotinib in patients with metastatic pancreati... 2008-03-26 bad-data
Completed, but no date, and reported results 2004-002985-39 A multicenter, randomized, controlled study comparing the efficacy and safety of 48 weeks of 40kD branched pegylated interferon alfa-2a (PEGASYS, Ro 25-8310) versus 96 weeks of PEGASYS, alone or in co... bad-data
Listed as ongoing, but also has a completion date and reported results 2004-003733-14 A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with mo... 2012-02-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-003741-40 A randomized, double-blind, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate, in patients with moderate... 2007-01-10 bad-data
Ongoing, reported early 2004-004021-98 A single arm phase IV study to assess efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folinic acid regimens as first line treatment for patients with me... not-yet-due
Ongoing 2004-004022-27 Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an α4 integrin antagonist, in combination with methotrexate, versus methotrexate alo... not-yet-due
Completed, reported early 2004-004110-17 Full title of the trial : An open-label, multicentre, dose-escalating phase I/II trial of 3-weekly rhuMAb 2H7 in patients with follicular non Hodgkin’s lymphoma 2008-01-21 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-004358-24 A phase IIIb/IV randomised, controlled study evaluating an intensification treatment strategy of adding enfuvirtide (ENF) to an oral Highly Active AntiRetroviral Therapy (HAART) in treatment experienc... 2008-04-28 bad-data
Ongoing 2004-004519-43 Estudio de Fase 2, Multicéntrico, Aleatorizado, Doble Ciego, Controlado con Placebo, de Grupos Paralelos y de Escalada de Dosis para determinar el Efecto del RO0506997 sobre las lesiones en Imagen de ... not-yet-due
Completed, but no date, and reported results 2004-004528-11 Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients wi... bad-data
Reported results 2004-004529-84 Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO0730699 in patients w... 2006-06-19 due-trials
Reported results 2004-004852-38 A randomized, open label, multicenter, parallel group study evaluating the efficacy and safety of 135 mcg and 90 mcg of Pegasys given as monotherapy to patients with chronic hepatitis C and end-stage ... 2008-12-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-005096-42 A phase II marker identification trial for Tarceva in second line NSCLC patients 2009-05-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-005210-37 A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD t... 2007-05-02 bad-data
Ongoing, reported early 2005-000285-39 Randomized Phase II Trial Testing the Efficacy of Three Bevacizumab-Containing First-Line Regimens for Metastatic Colorectal Cancer. not-yet-due
Completed, but no date, and reported results 2005-000336-25 Longitudinal analysis of HBV-specific T cell responses in patients with HBeAg-negative chronic hepatitis B (CHB) treated with pegylated interferon alfa-2a (40 KD) (PEGASYS, Ro 25-8310). Immunolog... bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000343-28 An optional continuation of double-blind treatment for subjects who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 A prospective, randomized,... 2006-11-08 bad-data
Ongoing, reported early 2005-000359-13 Hungarian Study of Maintenance after Rituximab Pretreatment. A multicentre, phase III, open-label study evaluating the benefit of a long-term MabThera® (rituximab) maintenance therapy in patients with... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-000387-39 An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positive ... 2010-07-07 bad-data
Not reported 2005-000535-18 Prospective, multicenter study to evaluate the renal safety of 6 mg ibandronic acid infusions over 15 min or 60 min in patients with metastatic bone disease due to breast cancer. 2006-05-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-000557-30 A phase II, open- label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab (Omnitarg™), a recombinant humanized antibody against HER2, in combination with ca... 2011-03-04 bad-data
Reported results 2005-000669-21 Pilot study of HIV Viral slope in naive patients treated with Enfuvirtide (ENF) based therapy compared to current standard treatment. 2008-08-28 due-trials
Completed, but no date, and reported results 2005-000802-30 Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer. bad-data
Completed, but no date, and reported results 2005-000859-15 Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults. bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000884-25 A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in pat... 2007-04-23 bad-data
Completed, but no date, and reported results 2005-001012-41 Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal Cancer bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001138-33 A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate MTX monotherapy, in patients with active rheumatoid arthritis. 2007-12-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001183-31 A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune) replacing CNI in a sta... 2006-06-01 bad-data
Completed, but no date 2005-001220-37 A pilot study of trastuzumab monotherapy in patients who progressed under a previous platinum-based or 5-fluoropyrimidin-based chemotherapy in metastatic or locally advanced gastric cancer bad-data
Reported results 2005-001502-11 “CHAIROS” – Early brief intensification by chemoimmunotherapy with FCR followed by FR and Rituximab maintenance in chemonaive patients with B-CLL – A phase II study 2012-09-24 due-trials
Not reported 2005-002239-29 A phase II prospective, open label, randomized, active-controlled, parallel group, multi-center ‘proof of concept’ trial in adult patients with complicated skin and skin structure infections requiring... 2007-02-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-002241-39 A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented adva... 2011-11-09 bad-data
Completed, but no date 2005-002385-11 - bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002392-32 A randomised, placebo controlled, double-blind, parallel group, international study to evaluate the safety and efficacy of rituximab (MabThera/Rituxan) in combination with methotrexate, compared to me... 2013-07-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002395-15 A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in met... 2013-07-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002396-33 A randomised, double-blind, international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate res... 2013-03-25 bad-data
Reported results 2005-002423-13 Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA17822 2012-05-02 due-trials
Completed, but no date 2005-002802-48 Evaluation of efficacy and safety of i.v. and oral ibandronate in elderly patients with bone metastases from solid tumors. A randomised phase II study bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002817-19 A randomised, double blind, placebo controlled multicentre study of the efficacy and safety of up to 100 days of valganciclovir vs up to 200 days of valganciclovir for prevention of cytomegalovirus di... 2009-08-13 bad-data
Completed, but no date, and reported results 2005-002818-38 ESPrES 500 - Evaluation of the safety profile of the new 500 mg film-coated tablet (FCT) formulation of boosted saquinavir (Invirase 500 mg) in HIV-1 infected patients bad-data
Reported results 2005-002907-18 A multi-center phase 2 randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO4389620 in patients with type 2 diabete... 2007-01-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-002908-42 A multi-center, double-blind, randomized, placebo-controlled dose-ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of RO4389620 in patients with type 2 diabetes... 2006-11-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002909-23 Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. 2013-04-24 bad-data
Reported results 2005-002910-39 A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 over a 24-week period in Patients with CHD or a CHD Risk Equivalent 2007-08-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-003220-19 A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva™ or comparator Alimta® (pemetrexed) or Taxotere® (docetaxel) in patients with histologically documented, adva... 2012-06-22 bad-data
Not reported 2005-003264-38 COMPARE: Comparison Ibandronate - Zoledronate regarding nephrotoxicity in patients with multiple myeloma 2009-04-03 due-trials
Ongoing, reported early 2005-003383-39 A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention o... not-yet-due
Completed, but no date 2005-003416-30 Phase II study of Dacarbazine with the anti-vascular endothelial growth factor antibody (Bevacizumab) in patients with unresectable/metastatic melanoma. bad-data
Listed as ongoing, but also has a completion date and reported results 2005-003493-19 An exploratory phase II, single arm, multicenter study to evaluate the efficacy and safety of the combination of pertuzumab and Herceptin® (trastuzumab) in patients with HER2-positive metastatic breas... 2015-09-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-003495-38 A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (MTX)... 2007-11-23 bad-data
Ongoing, reported early 2005-003632-22 An open-label, exploratory study of the pharmacokinetic and pharmacodynamic activity of rituximab in combination with methotrexate (MTX) in synovial tissue and in peripheral blood of patients with act... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-003694-25 A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoi... 2007-06-21 bad-data
Listed as ongoing, but also has a completion date 2005-003770-23 Comparative Trial inMultiple Myeloma Patients of Oral Ibandronic Acid versus Intravenous Zoledronate: a phase III study 2006-05-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-003862-40 A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line ... 2013-10-24 bad-data
Completed, but no date, and reported results 2005-003932-23 An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with... bad-data
Completed, but no date, and reported results 2005-004189-17 An open-label, single arm, multicenter study to assess the safety and efficacy of once-weekly administration of NeoRecormon using the 30.000 IU prefilled syringe in anaemic adult patients with solid t... bad-data
Completed, but no date, and reported results 2005-004216-70 A randomized, double-blind, parallel group, placebo-controlled with open-label active comparator arm , dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO07... bad-data
Reported results 2005-004268-21 A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249. 2007-07-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-004510-33 A randomized, controlled, open-label, multi-center, parallel-group study to compare the efficacy and safety of RO0503821 with that of darbepoetin alfa administered intravenously at extended dosing int... 2008-11-27 bad-data
Reported results 2005-004605-29 A Phase IIIb Study of Tarceva (Erlotinib) in patients with locally advanced, unresectable or metastatic pancreatic cancer 2011-04-27 due-trials
Completed, but no date, and reported results 2005-004662-16 Estudio fase I/II de la adición de erlotinib a la combinación de bevacizumab, capecitabina y oxaliplatino a dosis fijas, como terapia de primera línea en pacientes con adenocarcinoma colorrectal metas... bad-data
Reported results 2005-004695-20 Randomized multicenter trial comparing Valganciclovir CMV prophylaxis versus pre-emptive therapy after renal transplantation using proteomics for monitoring of graft alteration 2015-10-26 due-trials
Ongoing 2005-004760-23 “Estudio abierto, aleatorizado y comparativo, para establecer la seguridad y eficacia de Bondronat i.v. (6 mg) en pacientes con cáncer de mama y metástasis óseas, que presentan dolor de moderado a gra... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-004782-41 A parallel phase II study of Tarceva (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) non pre-treated by chemotherapy including dose escalation to toxicity in current a... 2009-11-10 bad-data
Ongoing 2005-004976-18 An Open-Label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine in Combination with Intravenous Docetaxel (Q3W) in Patients with Locally Advanced and/or Metastatic Breast Ca... not-yet-due
Reported results 2005-004977-12 A Phase IIIb study of MabThera rituximab maintenance therapy in patients with follicular Non-Hodgkin s Lymphoma who have responded to induction therapy. 2011-12-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-005399-34 A randomised, open-label, multi-national study to investigate the impact of bone marker feedback (at 2 months) on adherence to once monthly Ibandronate treatment for post-menopausal osteoporosis (PMO) 2007-09-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-005405-37 A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV nonsmall cell lung cancer receiving first line myelosuppressive chemotherapy 2007-06-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-005506-23 A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of Pegasys 180 µg plus Copegus 1000 or 1200 mg to the Currently Approved Combination of Pegasys 180 µg plus ... 2009-04-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-005507-41 Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Hig... 2009-04-22 bad-data
Reported results 2005-005529-74 A randomised, open-label, multi-national, multi-center study to investigate the impact of bone-marker feedback (at 3 months) on adherence to once monthly ibandronate treatment of patients with post-me... 2008-01-22 due-trials
Ongoing, reported early 2005-005533-35 An open-label, non-controlled study of bevacizumab in combination with cisplatin-gembitabine or carboplatin-paclitaxel, as first line treatment for patients with advanced or recurrent squamous non-sma... not-yet-due
Reported results 2005-005883-10 A phase II study of Bevacizumab with Docetaxel and Capecitabine in the neoadjuvant setting for breast cancer patients 2007-09-25 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-005887-97 Estudio abierto sobre bevacizumab(AVASTIN®) en combinación con quimioterapia basada en platino como tratamiento de primera línea de pacientes con carcinoma de pulmón no microcítico, no epidermoide, av... 2009-11-09 bad-data
Reported results 2005-006161-13 A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with metasta... 2010-01-21 due-trials
Reported results 2005-006162-33 Relationships between pharmacokinetic and pharmacodynamic strategies for assessment of the risks for acute rejection and side effects of mofetil mycophenolate 2008-09-09 due-trials
Completed, but no date, and reported results 2006-000011-15 A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of once monthly inbandronate in the prevention of glucocorticoid-induced osteoporosis in postmenopausal wome... bad-data
Reported results 2006-000026-31 Bevacizumab as treatment for patients with relapsed/refractory multiple myeloma 2008-07-31 due-trials
Completed, but no date 2006-000137-35 Prospective controlled clinical trial of metastatic breast cancer treatment with capecitabine/docetaxel in combination with beta epoetin as compared with sole capecitabine/docetaxel treatment bad-data
Reported results 2006-000254-51 A phase 2, multicenter, open label, titration study to assess the efficacy, safety and tolerability of RO4389620 in doses up to 200 mg BID in patients with type 2 diabetes mellitus not optimally contr... 2007-04-26 due-trials
Ongoing 2006-000608-18 Estudio abierto y aleatorizado, comparativo de la tolerabilidad renal de Bondronat® 6 mg I.V. en perfusión de 15 minutos frente a 60 minutos en pacientes con metástasis óseas not-yet-due
Completed, but no date, and reported results 2006-000703-42 A phase III randomized trial of trastuzumab continuation vs discontinuation in combination with 2nd-line chemotherapy after progression on a 1st-line trastuzumab-chemotherapy combination for HER2 ove... bad-data
Listed as ongoing, but also has a completion date and reported results 2006-000870-63 A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chronic... 2010-06-30 bad-data
Reported results 2006-000935-86 Randomized, multicentric, partially double blind placebo-controlled phase II study for examining the influence of Ribavirin on the initial virological response in previous untreated patients with chro... 2010-05-24 due-trials
Reported results 2006-000961-12 Prospective study to investigate if patients on reduced-dose EC-MPS treatment due to gastrointestinal problems can be switched to a higher than the equimolar dose of MMF 2007-10-31 due-trials
Listed as ongoing, but also has a completion date 2006-000977-31 PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG-POSITIVE CHRONIC HEPATITIS B IN ... 2013-09-04 bad-data
Not reported 2006-001000-37 Efficacy and safety of rituximab in patients with rheumatoid arthritis 2010-11-18 due-trials
Completed, but no date 2006-001011-29 A phase II study to assess the efficacy of intravenous loading doses of Bondronat 6 mg on metastatic bone pain in patients with breast cancer and skeletal metastases bad-data
Reported results 2006-001365-42 A randomized, open-label, 2-arm, multicentre, phase III study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab / docetaxel compared with trastuzumab / docetaxel alone... 2015-01-08 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-001434-41 An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using once every four weeks subcutaneous injections of RO0503821 in patients with chronic kidney diseas... 2009-10-07 bad-data
Completed, but no date, and reported results 2006-001517-15 Italian multicenter phase II trial using Fotemustine plus Bevacizumab as first-line therapy in metastatic melanoma. bad-data
Ongoing, reported early 2006-001518-34 Estudio fase II abierto, no aleatorizado, de erlotinib en combinación con gemcitabina en pacientes con adenocarcinoma de páncreas avanzado irresecable o metastásico: relación entre rash cutáneo y sup... not-yet-due
Not reported 2006-001682-42 Rituximab phase IIIb open-label, multi-centre assessment of safety and effectiveness in patients with RA following inadequate response to one prior anti-TNF inhibitor (RESET). 2009-05-01 due-trials
Ongoing, reported early 2006-001845-33 Estudio fase III randomizado, controlado de erlotinib (Tarceva®) como tratamiento de mantenimiento en pacientes con carcinoma epidermoide de cabeza y cuello resecado y tratado con radioterapia con o ... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2006-002119-28 Open label, randomized, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® (epoetin beta) therapy versus thrice weekly NeoRecormon®... 2006-11-21 bad-data
Reported results 2006-002180-72 Open Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6mg in Patients with Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, within ... 2009-01-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-002468-24 A double-blind, randomized, stratified, multi-center trial evaluating conventional and double dose oseltamivir in the treatment of immunocompromised patients with influenza 2017-05-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-002473-47 A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients. 2008-06-03 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-002525-23 A double-blind, placebo-controlled efficacy as assessed by post-bronchodilatator FEV1 and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate to severe C... 2010-05-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-002529-21 Estudio abierto de Bevacizumab (Avastin®) más Taxanos en monoterapia o en combinación, en primera linea de tratamiento de pacientes con cáncer de mama metastásico o locallmente recurrente(CMM o LR). 2013-06-25 bad-data
Reported results 2006-002860-25 A multicenter randomized phase III trial to compare trastuzumab (Herceptin®) continuation or discontinuation in combination with 2nd-line chemotherapies after progression on a 1st-line chemotherapy co... 2011-08-27 due-trials
Reported results 2006-003284-31 An open label multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in children 2007-05-23 due-trials
Completed, but no date, and reported results 2006-003291-35 Phase II, open label, neoadjuvant study of Bevacizumab in patients with inflammatory or locally advanced breast cancer bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003293-10 A randomised, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer 2013-03-08 bad-data
Completed, but no date, and reported results 2006-003441-16 OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS LOADING DOSE OF 3X 6MG IBANDRONIC ACID (BONDRONAT®) DURING 3 CONSECUTIVE DAYS IN PATIENTS WITH BREAST CANCER AND SKELETAL METASTASES... bad-data
Reported results 2006-003472-35 Essai randomisé de phase II évaluant l’efficacité et la tolérance de deux stratégies néoadjuvantes avec bevacizumab, visant à optimiser le traitement de patients atteints d’un cancer rectal localement... 2016-03-23 due-trials
Ongoing 2006-003821-10 Estudio aleatorizado, abierto y cruzado para evaluar la tolerabilidad del dispositivo de inyección sin aguja B2000 para la administración de enfuvirtida. not-yet-due
Completed, but no date, and reported results 2006-004032-75 An open-label, multi-center study to demonstrate the efficacy and safety of C.E.R.A when administered intravenously with pre-filled syringes (PFS) for the treatment of anemia in patients with chronic ... bad-data
Ongoing, reported early 2006-004093-27 A multicenter, phase II, open-label study evaluating the benefit of addition of MabThera (rituximab) to standard chemotherapies in patients with previously untreated mantle cell lymphoma. not-yet-due
Reported results 2006-004407-19 A multi-center, double-blind, randomized, placebo controlled, dose-ranging phase 2 study to investigate pharmacodynamics, safety, tolerability and pharmacokinetics of RO5073031 in patients with type 2... 2007-09-06 due-trials
Completed, but no date, and reported results 2006-004512-43 Estudio Fase II abierto de Capecitabina (Xeloda®) como fluoropirimidina de elección en combinación con quimioterapia en pacientes con cáncer gástrico Avanzado y/o Metastático susceptibles de ser trata... bad-data
Listed as ongoing, but also has a completion date and reported results 2006-004552-21 An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs darbepoetin alfa given according to local label in patient... 2010-08-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-004634-32 A randomized, open-label phase III Intergroup study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy (CTx) in patients with metastatic colorectal cancer and disease prog... 2013-05-31 bad-data
Reported results 2006-004673-98 Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blocker 2009-03-10 due-trials
Ongoing, reported early 2006-005144-84 Essai de phase II évaluant l’efficacité et la tolérance de bevacizumab associé à une chimiothérapie dans le traitement de patients atteints de tumeurs endocrines digestives bien différenciées, progres... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2006-005147-28 A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrex... 2016-04-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-005330-20 A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inade... 2013-08-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-005353-30 A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab in combination with methotrexate (MTX) compared to MTX alone in methotrexate- naïve p... 2013-08-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-005355-16 A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus 2008-05-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-005357-29 A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephritis ... 2013-10-23 bad-data
Reported results 2006-005370-49 Baltic post-marketing program of PEGASYS (Peginterferon-alfa-2a 40KD) in patients with HBeAg positive and HBeAg negative chronic hepatitis B 2010-08-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-005520-16 A multi-center, randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) ... 2011-11-30 bad-data
Ongoing, reported early 2006-005619-88 Estudio Fase II de bevacizumab en combinación con docetaxel y cisplatino, como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico metastásico o localmente avanzado not-yet-due
Completed, but no date, and reported results 2006-005621-28 A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in dialysis patients wit... bad-data
Listed as ongoing, but also has a completion date 2006-005747-29 Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs 2008-10-10 bad-data
Not reported 2006-005965-20 EFFECTS OF THREE TREATMENT STRATEGIES ON ANEMIA AND QUALITY OF LIFE IN PATIENTS WITH SOLID TUMORS OR LYMPHOPROLIFERATIVE MALIGNANCIES: A RANDOMIZED 3-ARM STUDY ON ACTIVE (A) OR CONVENTIONAL (C) TRANSF... 2007-04-19 due-trials
Not reported 2006-006111-77 Otevřená studie fáze II hodnotící bezpečnost a účinnost indukční analgetické léčby kyselinou ibandronovou (Bondronat) podávanou intravenózně po dobu 15 minut v dávce 6 mg 3 po sobě následující dny pac... 2008-09-30 due-trials
Completed, but no date 2006-006263-23 Efficacy of Oseltamivir treatment in laboratory- confirmed influenza: evaluation of effect on viral shedding and on serum and cytoplasmatic inflammatory cytokine concentration. bad-data
Listed as ongoing, but also has a completion date and reported results 2006-006273-25 A multi-center, double-blind, randomized, placebo-controlled, titration study to investigate the safety, the tolerability and the pharmacodynamic profiles of different doses of RO5073031 in patients w... 2007-10-17 bad-data
Completed, but no date, and reported results 2006-006349-15 A single arm, open label study to assess the efficacy, safety and tolerability of once- monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in dyalysis patients wi... bad-data
Listed as ongoing, but also has a completion date and reported results 2006-006359-11 A Phase II study of Tarceva in Combination with Avastin versus chemotherapy plus Avastin in 1st line advanced NSCLC patients 2011-05-12 bad-data
Reported results 2006-006523-40 A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis pati... 2009-06-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-006604-11 A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys® a... 2009-08-05 bad-data
Reported results 2006-006707-36 A single arm, open label study to assess the efficacy, safety, and tolerability of monthly administration of RO0503821 for the treatment of chronic renal anaemia in patients not on dialysis and not cu... 2010-06-22 due-trials
Completed, but no date, and reported results 2006-006746-33 Re-Treatment with Rituximab in patients with rheumatoid arthritis who have had an inadequate response to not more than one aTNF (extension study to ML19070) bad-data
Ongoing, reported early 2006-006865-17 Estudio multicéntrico, no aleatorizado, abierto, para valorar la eficacia y la seguridad de la combinación de micofenolato mofetilo (MMF), prednisona y eritropoyetina beta en pacientes con síndromes m... not-yet-due
Reported results 2007-000126-46 Einarmige, offene Studie zur Untersuchung der Wirksamkeit, Sicherheit und Verträglichkeit von monatlich subkutan verabreichtem C.E.R.A. an Patienten mit renaler Anämie, die noch nicht dialysepflichtig... 2010-06-11 due-trials
Ongoing, reported early 2007-000172-16 An open-label study to characterize the safety and response rate of MabThera (Rituximab) plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-000175-42 A double-blind, randomised, multicenter, phase III study of 2013-11-30 bad-data
Ongoing 2007-000226-43 BONDIR : Bonviva IV dans le traitement des Douleurs liées aux fractures vertébrales ostéoporotiques Récentes. Etude multicentrique, randomisée, comparative en double aveugle contrôlée versus placebo ... not-yet-due
Listed as ongoing, but also has a completion date 2007-000348-28 A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors. 2015-02-11 bad-data
Ongoing 2007-000593-24 An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-000872-18 A 12- week randomized, double blind, placebo - controlled, parallel group, 2- arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthriti... 2014-08-05 bad-data
Completed, reported early 2007-001103-37 An open-label, multicentre, non-randomised, dose-escalating phase I/II study, with a randomized phase II part, to investigate the safety and tolerability of RO5072759 given as monotherapy in patients ... 2012-07-03 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-001105-13 A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab in patients with locally adv... 2014-12-19 bad-data
Reported results 2007-001114-17 A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe ... 2011-01-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-001128-11 An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer. 2014-09-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001257-25 Ensayo clínico en fase 2 de búsqueda de dosis, multicéntrico, doble- ciego, aleatorizado y controlado con placebo para investigar la eficacia, seguridad, tolerancia y farmacocinética del inhibidor... 2008-04-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001585-33 A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (MabThera/Rituxan) in the inhibition of joint structural damage assessed by magnetic resonance imaging ... 2014-05-29 bad-data
Completed, but no date, and reported results 2007-001720-13 A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of subcutaneous RO0503821 for the maintenance of haemoglobine levels in patients with chro... bad-data
Completed, but no date, and reported results 2007-001721-97 An single arm, open label, interventional multicenter study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin le... bad-data
Completed, but no date, and reported results 2007-001754-11 Pilot study to evaluate the effect of Rituximab in combination with MTX in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by magnetic resonance imaging (MRI) in ... bad-data
Ongoing 2007-001904-18 An open label randomised controlled study to compare the efficacy, safety and tolerability of once every four weeks administration of subcutaneous C.E.R.A. versus darboepoetin alfa for the maintenance... not-yet-due
Ongoing, reported early 2007-001905-10 "Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A por vía subcutánea frente a darbepoetina alfa pa... not-yet-due
Ongoing, reported early 2007-002065-12 "Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez al mes de C.E.R.A por vía intravenosa frente a epoetina alfa para el mantenimie... not-yet-due
Reported results 2007-002135-83 An open label study to evaluate the effect of first line treatment with Tarceva in combination with Gemcitabine on disease progression in patients with unresectable advanced and/or metastatic non-smal... 2011-08-12 due-trials
Not reported 2007-002380-27 A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of intravenous C.E.R.A. for the maintanance of haemoglobin levels in dialysis patients ... 2009-07-29 due-trials
Ongoing, reported early 2007-002403-41 Etude clinique ouverte randomisée évaluant le traitement préventif par doxycycline sur la survenue d’éruption type folliculite lors du traitement par erlotinib chez les patients atteints d’un cancer b... not-yet-due
Reported results 2007-002733-36 “Estudio multicéntrico, no aleatorizado, abierto, en Fase II, para valorar la eficacia y seguridad de la inducción con Rituximab, Fludarabina, Ciclofosfamida seguido de Rituximab como mantenimiento (R... 2016-05-20 due-trials
Completed, but no date, and reported results 2007-002895-32 A phase II trial assessing Metronidazol Actavis 1% topical cream in the prevention and treatment of Erlotinib associated rash bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002960-85 Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 in outpatients on olanzapine, quetiapine, risperidone or paliperidone with prominent negative or disor... 2010-01-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002997-72 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PERTUZUMAB + TRASTUZUMAB + DOCETAXEL vs. PLACEBO + TRASTUZUMAB + DOCETAXEL IN PREVIOUSLY... 2018-01-29 bad-data
Ongoing, reported early 2007-003165-41 Étude prospective, multicentrique, ouverte et randomisée évaluant l’efficacité et la tolérance de Cellcept® (MMF) avec suivi thérapeutique pharmacologique, tacrolimus et épargne en corticoïdes versus ... not-yet-due
Ongoing 2007-003381-18 Etude multicentrique française, ouverte, non-comparative, évaluant la tolérance clinique et biologique de l’utilisation de l'epoetin beta (NeoRecormon®) chez des patients présentant une anémie au cour... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-003406-10 A Phase IIB, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of dalcetrapib by Measuring Flow Mediated Dilatation in the Brachial Art... 2010-05-06 bad-data
Completed, but no date 2007-003679-37 A single arm, open label study to assess the efficacy, safety, and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in haemodialysis pati... bad-data
Reported results 2007-003738-40 A phase II Biomarker Identification Trial for Erlotinib (Tarceva) in Patients with Advanced Pancreatic Carcinoma. 2015-03-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-003751-37 A Phase II, Dose-Escalation to rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer. 2012-02-20 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-003940-30 A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarcoma... 2014-02-19 bad-data
Listed as ongoing, but also has a completion date 2007-003955-35 A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients a... 2008-05-28 bad-data
Ongoing 2007-004014-13 Etude française, randomisée, controlée, parallèle, en ouvert, multicentrique, comparant le maintien du taux d’hémoglobine avec une administration mensuelle de C.E.R.A. (activateur continu du récepteur... not-yet-due
Reported results 2007-004169-16 Estudio fase II multicéntrico, abierto, no aleatorizado para evaluar la eficacia de una combinación con bevacizumab y quimioterapia secuencial, como tratamiento de pacientes con cáncer de mama operabl... 2011-03-07 due-trials
Ongoing 2007-004553-29 Essai en ouvert, randomisé et multicentrique évaluant l’efficacité et la tolérance de l’association de l’Enfuvirtide en cure d’induction de 3 mois à un traitement optimisé (TO) comprenant au moins 2 m... not-yet-due
Completed, reported early 2007-004617-34 A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old 2010-03-11 not-yet-due
Completed, reported early 2007-004824-19 Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study 2010-06-24 not-yet-due
Ongoing, reported early 2007-004969-18 Open-label, efficacy and safety study of bevacizumab (Avastin) in combination with XELOX (Oxaliplatin plus Xeloda) for the first-line treatment of patients with locally advanced or metastatic cancer o... not-yet-due
Reported results 2007-004993-15 A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Virol... 2012-05-02 due-trials
Ongoing, reported early 2007-005017-19 Estudio abierto, multicéntrico y aleatorizado en fase II para evaluar la adición de bevacizumab a la quimioterapia en niños y adolescentes con diganóstico inicial de sarcoma metastásico de tejidos bla... not-yet-due
Reported results 2007-005037-11 An open-label, randomized 2-period crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of warfarin in combination with oseltamivir in volunteers stabilized o... 2008-07-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-005103-18 A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndr... 2012-07-06 bad-data
Listed as ongoing, but also has a completion date 2007-005129-31 A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on... 2017-07-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-005182-35 A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemoth... 2014-04-17 bad-data
Completed, but no date, and reported results 2007-005528-34 Subcutaneous Treatment of Anemia in patients with a GFR Below 45 ml/min/1.73m2 through Injections with Mircera as low frequent as Once monthly bad-data
Ongoing 2007-005757-28 Etude française multi-centrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des pa... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-005759-41 A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with Ac... 2013-08-05 bad-data
Completed, but no date, and reported results 2007-005799-15 A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in haemodialysis patient... bad-data
Ongoing, reported early 2007-005939-28 Estudio de fase I/II multicéntrico, abierto, de escalada de dosis, para evaluar la seguridad, farmacocinética y actividad de RO5083945, un anticuerpo glico-modificado anti-EGFR, en pacientes con tumor... not-yet-due
Not reported 2007-006231-31 A mono center, open-label glucose clamp study examining the metabolic effect of the frequency of insulin infusion intervals for basal insulin infusion in patients with type 1 diabetes 2008-03-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-006338-32 Estudio en fase II de búsqueda de dosis, multicéntrico, aleatorio, de grupos paralelos, parcialmente enmascarado, con placebo y Avonex® como fármacos control, para evaluar la eficacia, determinada por... 2011-02-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-006611-23 Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcin... 2012-12-03 bad-data
Reported results 2007-007758-70 An open-label multi-center, multiple dose study to determine the optimum starting dose of intravenous MIRCERA® for maintenance treatment of anemia in pediatric patients with chronic kidney disease on ... 2016-03-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-007863-26 A multicentre randomized phase II study to assess the safety and resectability in patients with primarily unresectable liver metastases secondary to colorectal cancer receiving 1st line treatment eith... 2013-10-21 bad-data
Completed, but no date, and reported results 2008-000105-11 Effectiveness after 4 and 24 weeks and safety of tocilizumab in patients with active RA bad-data
Listed as ongoing, but also has a completion date and reported results 2008-000587-17 Estudio abierto, multinacional para evaluar la seguridad, tolerabilidad y eficacia de tocilizumab en pacientes con artritis reumatoide activa en tratamiento con FAMEs no biológicos que tienen una resp... 2010-03-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-000662-23 A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who... 2012-09-18 bad-data
Completed, but no date, and reported results 2008-000783-16 Multicenter, phase II trial assessing the efficacy and safety of bevacizumab (Avastin®) combined to trastuzumab (Herceptin®) based chemotherapy in patients with primary inflammatory HER2+ breast cance... bad-data
Reported results 2008-001122-13 Multi-center, randomized, double-blind, 5-arm parallel group, placebo controlled 4 week study to investigate the safety, tolerability and efficacy of two doses each (near to maximum tolerated dose and... 2009-08-24 due-trials
Not reported 2008-001180-11 An Open-label, single-arm, Phase II study to evaluate the efficacy and the feasibility of bevacizumab (Avastin®) based on a FOLFOXIRI regimen until progression in patients with previously untreated me... 2014-02-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-001249-24 A multi-center, double-blind, randomized, parallel group, placebo-controlled 12-week study to investigate glycemic parameters of efficacy, safety/ tolerability and pharmacokinetics of five dose levels... 2009-10-29 bad-data
Completed, but no date, and reported results 2008-001612-20 A study of chlorambucil plus MabThera as induction therapy followed in responders by maintenance therapy versus observation on response rate in patients ≥ 60 years with previously untreated chr... bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001736-12 A Randomized, double blind study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva), on progression-free survival in patients with advanced... 2011-07-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001744-39 A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes mell... 2010-09-23 bad-data
Ongoing, reported early 2008-001747-18 Etude multicentrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insu... not-yet-due
Ongoing, reported early 2008-001762-85 An open label study to determine the effect of R1507 (RO4858696) plus Tarceva (erlotinib) on progression-free survival in patients with stage IIIB/IV non-small cell lung cancer with progressive diseas... not-yet-due
Ongoing, reported early 2008-001765-28 A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in patients with type 2 diabetes melli... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-001847-20 Estudio aleatorizado, controlado con placebo, para evaluar la seguridad y eficacia de añadir tocilizumab (TCZ) a metotrexato (MTX) frente al cambio a TCZ (controlado con placebo), con la posibilidad d... 2013-01-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001854-42 A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to sitagliptin and plac... 2011-01-11 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001855-23 A multi-center, randomized, open-label, active-controlled study to compare the efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin glargine in insulin-naive type 2 diabetic ... 2011-01-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001856-36 A multicenter, randomized, open label, active-comparator controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to exenatide in patients with type 2 di... 2011-01-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-002022-10 An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participat... 2012-03-23 bad-data
Ongoing, reported early 2008-002298-11 Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5126766, a dual Raf and MEK inhibitor, administered orally as monotherapy in patients w... not-yet-due
Completed, but no date 2008-002381-55 Evaluación de la Eficacia de Rituximab en pacientes con Artritis Reumatoide a través de la medición, por Resonancia Magnética de Mano, de los parámetros clínicos de la enfermedad. Estudio RESONAR. bad-data
Listed as ongoing, but also has a completion date and reported results 2008-002819-40 A randomized, multicenter, phase II study of the efficacy and safety of TRASTUZUMAB-MCC-DM1 vs. TRASTUZUMAB (HERCEPTIN) and DOCETAXEL (TAXOTERE) in patients with metastatic HER2-positive breast cancer... 2012-05-23 bad-data
Completed, but no date, and reported results 2008-003173-40 A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis patient... bad-data
Listed as ongoing, but also has a completion date and reported results 2008-003283-20 A single arm, open-label, phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast c... 2013-03-14 bad-data
Reported results 2008-003460-19 An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease. 2013-03-14 due-trials
Reported results 2008-003575-47 A randomized, double-blind, placebo controlled, parallel group study to investigate the effect of Taspoglutide on gastric emptying measured by a paracetamol test after single dose and after multiple d... 2009-07-27 due-trials
Ongoing, reported early 2008-003657-32 Estudio abierto fase II de bevacizumab en combinación con paclitaxel y gemcitabina como tratamiento de primera línea en pacientes diagnosticados de carcinoma de mama metastasico o localmente avanzado ... not-yet-due
Completed, but no date, and reported results 2008-003980-38 An open label study of the effect of Xeloda and radiotherapy on pathological response rate in patients with locally advanced rectal cancer. bad-data
Listed as ongoing, but also has a completion date and reported results 2008-004012-13 A dose ranging, randomized, double blind, parallel-group placebo-controlled multi-center study of RO5313534 used as add-on to donepezil treatment in patients with mild to moderate symptoms of Alzh... 2010-11-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-004013-94 A prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial expo... 2013-02-18 bad-data
Completed, but no date 2008-004126-16 Local Open-Label Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-... bad-data
Completed, reported early 2008-004128-22 An exploratory study to evaluate the biological activity of R1507, a human monoclonal antibody, antagonist of the insulin-like growth factor receptor (IGF-1R) in women with operable breast cancer 2010-02-15 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-005525-11 A randomized, placebo controlled, double-blind, parallel group study to compare the safety and efficacy of the combination of rituximab (MabThera) and tocilizumab (Actemra) versus tocilizumab therapy ... 2013-03-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005713-22 A randomized, multicenter, phase III open-label study of the efficacy and safety of trastuzumab-MCC-DM1 vs. capecitabine + lapatinib in patients with HER2-positive locally advanced or metastatic breas... 2015-11-03 bad-data
Ongoing, reported early 2008-005806-38 A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with adva... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-005809-20 A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in obese patients with type 2 diabetes... 2010-05-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-006146-26 A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and ... 2015-09-09 bad-data
Reported results 2008-006384-37 A phase II study of orally administered RO4929097, a gamma-secretase inhibitor, as a single agent in patients with recurrent or refractory Non-Small Cell Lung Cancer (NSCLC). 2010-08-16 due-trials
Completed, but no date, and reported results 2008-006443-39 Estudio piloto de fase II multicéntrico, aleatorizado, en grupos paralelos para comparar la incidencia de las reacciones a la infusión de Tocilizumab en pacientes con AR moderada a grave cuando la inf... bad-data
Ongoing, reported early 2008-006504-33 Etude multicentrique, en ouvert, non randomisée de phase II évaluant l’efficacité de bevacizumab (Avastin®) associé à paclitaxel/carboplatine en première ligne ou à erlotinib en deuxième ligne de trai... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-006801-17 A multicenter randomized phase III study to compare the combination of trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progr... 2017-08-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-006872-31 A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed duri... 2014-06-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-006924-68 Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs... 2012-04-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-006946-24 A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high gr... 2013-09-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-007008-27 Estudio abierto de terapia de mantenimiento con bevacizumab (AVASTIN) con o sin pemetrexed tras una quimioterapia de primera línea con bevacizumab-cisplatino-pemetrexed en pacientes con cáncer de pulm... 2012-05-25 bad-data
Completed, but no date 2008-007057-12 A Randomized open label study of the effect of first line combination treatment with Avastin (bevacizumab) plus paclitaxel and gemcitabine Compared With Avastin (bevacizumab) plus paclitaxel on ob... bad-data
Listed as ongoing, but also has a completion date and reported results 2008-007326-19 A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive e... 2017-01-24 bad-data
Ongoing, reported early 2008-007349-30 Open-label, phase II, randomized, comparative, multicentre trial of concurrent Whole Brain Radiation Therapy (WBRT) and capecitabine (Xeloda®) followed by maintenance capecitabine compared with standa... not-yet-due
Ongoing 2008-007350-35 A single arm, open-label trial assessing the effect of Capecitabine (Xeloda®) on progression-free survival rate at four months in breast cancer patients with CNS progression after whole brain radiothe... not-yet-due
Not reported 2008-007495-20 A single arm, open-label, multicentre, phase II study to evaluate the efficacy and safety of bevacizumab and trastuzumab combination and sequential capecitabine in patients with HER2-positive locally ... 2011-06-06 due-trials
Listed as ongoing, but also has a completion date 2008-008258-21 A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasy... 2012-01-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-008276-14 A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanc... 2011-08-11 bad-data
Ongoing, reported early 2008-008309-23 Etude clinique comparative en double aveugle versus placebo sur la rapidité d’action du tocilizumab sur le soulagement des patients atteints de polyarthrite rhumatoïde active avec réponse inadéquate a... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-008336-85 AA single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer 2013-06-14 bad-data
Completed, but no date, and reported results 2008-008739-27 Randomised phase II trial of bevacizumab (AVASTIN) in combination with gemcitabine or attenuated doses of cisplatin and gemcitabine as first-line treatment of elderly patients with advanced, metastati... bad-data
Listed as ongoing, but also has a completion date and reported results 2009-009157-24 A multicenter, randomized, double blind (double dummy), active comparator controlled study to compare the efficacy, safety and tolerability of taspoglutide versus pioglitazone in type 2 diabetes patie... 2011-01-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-009608-38 A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copeg... 2011-07-04 bad-data
Ongoing, reported early 2009-010000-28 An open-label, multi-center study of the safety and tolerability of the combination of Trastuzumab-MCC-DM1 (T-DM1) with docetaxel, and potentially pertuzumab, for treatment for patients with advanced ... not-yet-due
Reported results 2009-010390-21 A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy fol-lowed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temo-zolomide monotherapy in... 2014-08-30 due-trials
Completed, but no date, and reported results 2009-011105-17 A single-arm, open-label study of early improvement of anemia and fatigue during treatment with tocilizumab (TCZ) in combination with non biologic DMARDs, in adult patients with moderate to severe act... bad-data
Not reported 2009-011400-33 A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or ... 2014-08-29 due-trials
Completed, but no date, and reported results 2009-011433-27 A phase II multicenter open-label study of MabThera (Rituximab) addition to regularly prescribed chemotherapy in patients with untreated Mantle Cell Lymphoma bad-data
Completed, but no date, and reported results 2009-011520-53 Evaluation of Adherence and Persistence to Tocilizumab in combination with Methotrexate or Tocilizumab Monotherapy in patients with moderate to severe active rheumatoid arthritis in local environment bad-data
Listed as ongoing, but also has a completion date and reported results 2009-011593-15 A 24 week randomized double-blind, placebo controlled withdrawal trial with a 16 week open label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of tocilizumab in ... 2013-08-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-012019-17 A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy... 2016-01-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-012072-28 A randomized Phase IIIb study of MabThera ® (rituximab) added to a chemotherapy, bendamustine or chlorambucil, in patients with Chronic Lymphocytic Leukemia. 2014-03-31 bad-data
Reported results 2009-012090-36 A single-arm, open-label phase II study: Treatment beyond progression by adding Bevacizumab to XELOX or FOLFOX chemotherapy in patients with metastatic colorectal cancer and disease progression, under... 2012-01-16 due-trials
Completed, but no date 2009-012185-32 Open label, multicentric phase IIIb study to evaluate the effect of tocilizumab in combination with DMARDs in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by d... bad-data
Reported results 2009-012218-30 A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 week... 2011-09-30 due-trials
Reported results 2009-012231-15 Pharmacokinetics of Mycophenolate Mofetil in de novo lung allograft recipients 2012-06-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-012269-71 Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D) 2013-07-10 bad-data
Reported results 2009-012270-12 Effects of 150 μg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos. 2012-07-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-012293-12 BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma with V600E BRAF Mutation Receiving RO51854... 2015-07-08 bad-data
Reported results 2009-012355-15 Vergleich der Pharmakokinetik von Mycophenolatmofetil und Mycophenolat-Natrium bei Calcineurininhibitor-frei behandelten nierentransplantierten Patienten. 2010-04-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-012476-28 An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb)or chlorambucil (Clb) alone in ... 2017-08-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-012759-12 A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy and ... 2013-07-15 bad-data
Completed, but no date, and reported results 2009-013316-12 A multi-center, randomized, double blind, placebo controlled study to evaluate remission in DMARD and biological naïve early reumatoid arthritis (RA) subjects treated with tocilizumab (TCZ) plus tigh... bad-data
Completed, report not yet due 2009-013410-26 An open-label, randomized, multicenter, phase II, comparative, exploratory study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according t... 2017-12-13 not-yet-due
Ongoing, reported early 2009-014279-37 Open-Label study of bevacizumab (Avastin®) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-014365-12 An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants 0 to < 12 months of age with confirmed influenza infection. 2012-04-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-014986-22 A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in patients with inadequately controlled type 2 diabetes and e... 2011-01-31 bad-data
Reported results 2009-015114-22 A randomized controlled, single-blind, proof- of- concept-study to investigate the protective effects of early treatment with C.E.R.A. in patients with chronic kidney disease on renal disease progress... 2015-03-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-015845-21 A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneou... 2012-01-31 bad-data
Listed as ongoing, but also has a completion date 2009-016560-36 A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated wi... 2015-03-31 bad-data
Completed, but no date, and reported results 2009-017063-42 Biomarkers Impact On the response to Treatment with Erlotinib in first line non-small cell lung Cancer with EGFR activating mutations bad-data
Listed as ongoing, but also has a completion date and reported results 2009-017443-34 A Ph II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab vers... 2011-10-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-017488-40 A randomized, double-blind, parallel-group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus placebo in patients with ankylos... 2011-10-12 bad-data
Reported results 2009-017725-19 A Phase IIIB multicenter, double-blind, randomized, placebocontrolled study, evaluating the effect of treatment with dalcetrapib 600 mg on Atherosclerotic Disease as measured by I. Coronary Intravascu... 2012-05-07 due-trials
Completed, but no date, and reported results 2009-017848-14 Estudio fase II de capecitabina- oxaliplatino-trastuzumab (XELOX-trastuzumab) como tratamiento perioperatorio de pacientes con adenocarcinoma gástrico o de la unión gastroesofágica, resecable (estadio... bad-data
Listed as ongoing, but also has a completion date and reported results 2009-017905-13 A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus t... 2016-09-16 bad-data
Reported results 2010-018331-18 A 52 week, Single center, Open-label Study to Evaluate Neutrophil function and survival effects of Tocilizumab (TCZ) in Patients with Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs... 2012-03-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-018375-22 A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease-modifying anti-rheumatic ... 2013-08-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-018476-24 A prospective double-blind randomized Phase III study of 300 mg vs. 150 mg erlotinib in current smokers with locally advanced or metastatic NSCLC in second-line setting after failure on chemotherapy 2014-02-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-018945-72 A randomized, multicenter, open-label phase Ib/II study of RO5083945 in combination with cisplatin and gemcitabine/pemetrexed versus cisplatin and gemcitabine/pemetrexed in patients with advanced or r... 2013-07-30 bad-data
Reported results 2010-019051-21 Estudio de un único brazo, fase II de bevacizumab en combinación con temozolomida en pacientes con glioblastoma multiforme recurrente 2013-05-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019525-34 Global study to assess the addition of bevacizumab to carboplatin and paclitaxel as front-line treatment of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma. 2015-03-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-019584-10 A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir... 2012-12-03 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-019585-90 A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Combin... 2013-01-25 bad-data
Reported results 2010-019694-15 Act-Alone : An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorticoi... 2013-03-05 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019752-50 A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1 sequentially with anthracyline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients wi... 2013-06-12 bad-data
Ongoing, reported early 2010-019895-66 Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, con grupos de tratamiento paralelos, de dos años de duración, para evaluar el efecto de RO4909832 administrado por vía subcután... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-019912-18 A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs... 2013-11-27 bad-data
Completed, but no date, and reported results 2010-019935-37 A pragmatic, randomized, parallel group study of the effect on disease remission, work productivity, and tolerability of tocilizumab in combination with DMARDs and individually designed best practice ... bad-data
Listed as ongoing, but also has a completion date and reported results 2010-020065-24 A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to... 2016-03-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-020083-38 A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged ≥ 13 Years. 2012-09-14 bad-data
Completed, but no date, and reported results 2010-020229-42 A randomized phase II trial of erlotinib (TARCEVA) or intermittent dosing of erlotinib and docetaxel in male former smokers with locally advanced or metastatic squamous nonsmall cell lung cancer (N... bad-data
Ongoing, reported early 2010-020315-36 A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Scler... not-yet-due
Ongoing, reported early 2010-020337-99 A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Scler... not-yet-due
Ongoing, reported early 2010-020338-25 A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis not-yet-due
Ongoing, reported early 2010-020370-42 A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega... not-yet-due
Reported results 2010-020467-21 A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega... 2014-06-09 due-trials
Reported results 2010-020470-42 A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega... 2014-04-14 due-trials
Reported results 2010-020616-11 Estudio en fase III, multicéntrico, aleatorizado, de 12 semanas, doble ciego, con grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de RO4917838 en pacientes con síntom... 2014-09-06 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-020696-23 Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms... 2014-06-09 bad-data
Reported results 2010-020718-26 Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms... 2014-11-12 due-trials
Reported results 2010-020998-16 A Phase III randomized study evaluating the efficacy and safety of continued and re-induced bevacizumab in combination with chemotherapy for patients with locally recurrent or metastatic breast cancer... 2015-03-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-021067-32 An open-label, multicenter extension study of trastuzumab emtansine administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Genentech and... 2013-09-24 bad-data
Reported results 2010-021120-96 A study to assess the incidence of mutations in the tyrosine kinase domain of the epidermal growth factor receptor in UK patients with newly diagnosed locally advanced or metastatic non-small cell lu... 2014-04-24 due-trials
Completed, but no date, and reported results 2010-021172-28 Farmacocinética y seguridad de valganciclovir en pacientes pediátricos < 4 meses de edad, receptores de trasplante cardíaco. Pharmacokinetics and safety of valganciclovir in pediatric heart transplant... bad-data
Completed, but no date, and reported results 2010-021191-29 A multicenter, open label study to assess the effect of trastuzumab + Whole Brain Radiotherapy (WBRT) on brain metastases from HER-2 positive breast cancer. bad-data
Listed as ongoing, but also has a completion date and reported results 2010-021377-36 A two stage phase III, international, multi center, randomized, controlled, open-label study to investigate the pharmacokinetics, efficacy and safety of rituximab SC in combination with CHOP or CVP ve... 2017-10-23 bad-data
Reported results 2010-021984-33 A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exacer... 2012-09-10 due-trials
Reported results 2010-022049-88 "Efficacy and safety study of a sequential therapy of tocilizumab (TCZ) and, if initially inade-quately responded to tocilizumab (TCZ), followed by rituximab (RTX) in DMARD-IR patients with rheumatoid... 2014-02-19 due-trials
Reported results 2010-022067-35 INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease 2012-10-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-022189-28 A phase II open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma 2014-05-20 bad-data
Completed, report not yet due 2010-022509-17 Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lung cancer who present activating mutations in the tyrosine kinase domain o... 2017-09-29 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-022514-47 Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets 2013-05-23 bad-data
Reported results 2010-022529-14 A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in patie... 2012-03-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-022645-14 An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced non... 2016-06-24 bad-data
Ongoing, reported early 2010-022902-41 A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-022983-11 A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type... 2013-12-19 bad-data
Listed as ongoing, but also has a completion date 2010-023407-95 A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lym... 2018-06-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-023526-21 An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma 2017-02-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-023587-40 A randomized, double-blind, parallel-group study of the reduction of signs and symptoms during treatment with tocilizumab versus adalimumab, both in combination with MTX, in patients with moderate ... 2012-08-30 bad-data
Reported results 2010-023763-17 A phase II double-blind placebo-controlled randomized study of GDC-0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase inhib... 2016-04-07 due-trials
Reported results 2010-023869-21 A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal gro... 2013-10-11 due-trials
Ongoing, reported early 2010-023892-24 Phase II, open-label study of erlotinib (Tarceva) treatment In patients with locally advanced or metastatic non-small-cell lung cancer who present activating mutations in the tyrosine kinase domain of... not-yet-due
Reported results 2010-024061-48 Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who present activating mutations in the tyrosine kina... 2014-01-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-024099-25 A randomized, multi-center cross-over study to evaluate patient preference and Health Care Professional (HCP) satisfaction with subcutaneous (SC) administration of trastuzumab in HER2-positive early b... 2015-12-07 bad-data
Ongoing, reported early 2010-024132-41 A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMP... not-yet-due
Reported results 2010-024133-23 An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resistant ... 2015-05-29 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-024194-39 A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED TRIAL COMPARING THE EFFICACY OF GA101 (RO5072759) IN COMBINATION WITH CHOP (G-CHOP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS... 2018-01-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-024468-16 A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva vs Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSC... 2016-01-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-000195-34 A single arm, open-label, phase II, multicentre study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC). 2017-07-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-000509-29 A Phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of T-DM1 compared with treatment of physician’s choice in patients with HER2-positive metastatic breast cancer w... 2015-08-31 bad-data
Completed, reported early 2011-000640-24 A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HCV N... 2011-12-08 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-000874-67 An open-label, multicenter, single-arm, Phase I dose-escalation with 2015-12-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-000954-46 An open-label, single-arm, phase II, multicenter study to evaluate 2015-07-30 bad-data
Ongoing 2011-001096-39 An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics not-yet-due
Completed, but no date, and reported results 2011-001097-25 Long-term, interventional, open label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Germany who completed the ... bad-data
Reported results 2011-001256-10 Open-label, multicenter phase IV study of ribavirin (Copegus®) combined with standard treatment to assess correlation between hemoglobin decrease and rate of sustained virological response in patients... 2014-01-22 due-trials
Completed, but no date, and reported results 2011-001363-46 RANDOMIZED, NON COMPARATIVE PHASE II TRIAL WITH BEVACIZUMAB AND FOTEMUSTINE IN THE TREATMENT OF RECURRENT GLIOBLASTOMA. bad-data
Completed, but no date, and reported results 2011-001364-22 A multi-center, open-label clinical trial to evaluate the objective response rate of bevacizumab in combination with modified FOLFOX-6 followed by one year of maintenance with bevacizumab alone in pat... bad-data
Completed, but no date, and reported results 2011-001365-40 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of 2 Doses of RO4905417 (R1512) Administered to Patients with Non ST-Elevation Myocardial Infarcti... bad-data
Reported results 2011-001436-33 A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response to on... 2013-11-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-001460-22 A Phase II/III, Multicenter, Randomized, Double Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis 2015-06-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-001526-19 A randomized, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/ capecitabine chemotherapy, as first-line therapy in patients with ... 2015-08-25 bad-data
Completed, but no date, and reported results 2011-001626-15 A multi-centre, randomized, double-blind study of the safety and efficacy of tocilizumab (TCZ) in combination with methotrexate (MTX), versus TCZ (placebo controlled) in patients with active rheumatoi... bad-data
Reported results 2011-001863-39 A multi-center study of the safety and effect on disease activity of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus Tocilizumab monotheraphy in patients with mild to moderate rheumato... 2014-02-13 due-trials
Not reported 2011-001891-21 A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary Hear... 2012-05-07 due-trials
Listed as ongoing, but also has a completion date 2011-002009-31 A single arm open label multicentre extension study of bevacizumab in patients with solid tumours on study treatment with bevacizumab at the end of a F. Hoffmann-La Roche and/or Genentech sponsored st... 2017-11-22 bad-data
Ongoing, reported early 2011-002132-10 A randomized, two-arm, open-label, multicenter Phase II trial not-yet-due
Reported results 2011-002160-24 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients with Major Depr... 2014-06-04 due-trials
Reported results 2011-002168-26 OPEN LABEL STUDY OF ERLOTINIB (TARCEVA®) AS SINGLE AGENT FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LUNG ADENOCARCINOMA WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR... 2015-01-30 due-trials
Completed, reported early 2011-002331-25 An Open-Label, Randomized, Multicenter Phase IIa Study 2017-10-31 not-yet-due
Reported results 2011-002363-15 Multicenter, randomized, parallel group study to compare the incidence of Tocilizumab related infusion reactions in patients with moderate to severe active RA, when infusion is given over 31 minutes c... 2013-09-02 due-trials
Reported results 2011-002714-37 A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION... 2014-02-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-002715-28 A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION... 2014-01-30 bad-data
Ongoing, reported early 2011-002732-70 A phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, Ro 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B in the... not-yet-due
Reported results 2011-003308-18 A two-cohort, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab and vinorelbine in first line patients with HER2-positive adv... 2015-10-15 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-003574-84 A Randomized, Placebo-controlled, Double-blind, 2015-08-20 bad-data
Reported results 2011-003617-42 An adaptive, multi-center, randomized, investigator-masked, 2012-11-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-003719-42 A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH EITHER BEVACIZUMAB + PLATINUM + PACLITAXEL OR PEMETREXED + ... 2015-11-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-003720-12 A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH PACLITAXEL + CISPLATIN OR CARBOPLATIN AS FIRST-LINE TREATME... 2015-09-20 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-004011-24 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR RECURR... 2018-07-13 bad-data
Reported results 2011-004129-28 Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR in Combination With Peginterferon Alfa-2a Plus Ribavirin in Treatment-naive Patients and... 2013-08-28 due-trials
Completed, but no date 2011-004205-24 A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second con... bad-data
Completed, but no date 2011-004218-41 A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second con... bad-data
Listed as ongoing, but also has a completion date and reported results 2011-004349-42 A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome. 2014-04-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-004426-10 An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers 2016-10-27 bad-data
Reported results 2011-004810-41 An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in tr... 2014-06-20 due-trials
Ongoing, reported early 2011-005260-20 Randomised, Phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheum... not-yet-due
Ongoing, reported early 2011-005328-17 A phase III prospective, two-cohort non-randomised, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in patient... not-yet-due
Ongoing 2011-005334-20 A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2011-005335-97 A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel compared with... 2017-11-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-005912-27 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2016-01-21 bad-data
Reported results 2011-005975-17 A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in wom... 2016-04-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-006022-25 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS 2018-06-04 bad-data
Reported results 2011-006125-14 A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS 2014-12-18 due-trials
Completed, but no date, and reported results 2012-000080-25 A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks Peginterferon alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype... bad-data
Listed as ongoing, but also has a completion date and reported results 2012-000180-25 A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma who are on inhaled corti... 2016-12-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-000190-24 A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID–SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID-DEPENDENT ASTHMA. 2016-12-21 bad-data
Ongoing 2012-000444-10 A PHASE IV STUDY TO EVALUATE DECREASED DOSE FREQUENCY IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WHO EXPERIENCE LABORATORY ABNORMALITIES DURING TREATMENT WITH TOCILIZUMAB not-yet-due
Reported results 2012-000638-21 A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with or without Mericitabine in treatm... 2013-11-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000660-22 A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treated ... 2016-04-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-000669-19 A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTER, PHASE IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC) RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN COMBINATION WITH CHOP (R-... 2016-09-16 bad-data
Reported results 2012-000671-16 A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities 2013-07-10 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000943-29 A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO BACKGROUND ALZHEIMER'S DISEASE THERAPY IN PATIE... 2015-06-03 bad-data
Reported results 2012-001144-22 A RANDOMIZED, OPEN-LABEL, PHASE II STUDY ASSESSING THE EFFICACY AND THE SAFETY OF BEVACIZUMAB IN NEOADJUVANT THERAPY IN PATIENTS WITH FIGO STAGE IIIC/IV OVARIAN, TUBAL OR PERITONEAL ADENOCARCINOMA, IN... 2016-08-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-001402-23 A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5-FLUOROURACIL, FOLINIC ACID, AND OXALIPLATI... 2015-12-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-001547-46 Phase I followed by phase II study of the combination of trastuzumab emtansine (T-DM1) and capecitabine in HER2-positive metastatic breast cancer and HER2-positive locally advanced or metastatic gastr... 2017-05-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-001628-37 A multicenter, single arm study of trastuzumab emtansine (T-DM1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti-HER2 and chemotherapy-based treatme... 2016-10-20 bad-data
Reported results 2012-001639-29 A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to assess the effect of Aleglitazar on cardiac energetics and function in patients with uncomplicated type 2 di... 2013-07-10 due-trials
Ongoing 2012-002018-37 A RANDOMIZED, MULTICENTER, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BREAST... not-yet-due
Ongoing 2012-002062-13 A Phase IIa, International, Multicenter, Open-Label, Uncontrolled not-yet-due
Completed, but no date, and reported results 2012-002632-87 Estudio de extensión a largo plazo de los estudios WA22762 y NA25220, multicéntrico, abierto para evaluar la seguridad y eficacia de tocilizumab subcutáneo en pacientes con artritis reumatoide moderad... bad-data
Ongoing 2012-002633-11 An open label, randomised, adaptive, multicenter, pharmacokinetic/pharmacodynamic, phase Ib, study of oseltamivir (Tamiflu®) in the treatment of influenza in immunocompromised children, between 0-18 y... not-yet-due
Reported results 2012-002649-39 A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY TO ASSESS THE EFFICACY OF ALEGLITAZAR ON INSULIN SENSITIVITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE INADE... 2013-09-03 due-trials
Completed, but no date, and reported results 2012-002777-56 Cross-sectional multicenter study evaluating the IL28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon alfa-2a in the course of Peg.Be.Liver study bad-data
Ongoing, reported early 2012-003008-11 A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR ME... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-003138-17 A double-blind, placebo-controlled, randomised, Phase IIIb study evaluating the efficacy and safety of addition of continuous multiple line bevacizumab treatment to lomustine in second (2nd)-line foll... 2017-06-05 bad-data
Ongoing 2012-003144-80 AN OPEN-LABEL, EXTENSION (ROLLOVER) STUDY OF VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION−POSITIVE MALIGNANCIES PREVIOUSLY ENROLLED IN AN ANTECEDENT VEMURAFENIB PROTOCOL not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-003230-17 A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFU... 2016-12-20 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-003305-10 A randomized, double-blinded, regimen controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas (BC... 2016-08-31 bad-data
Ongoing 2012-003442-32 AN OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE III STUDY IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER RESPONDING TO FIRST LINE TREATMENT WITH INTRAVENOUS TRASTUZUMAB FOR AT LEAST 3 YEARS AND ... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-003486-18 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH POLYARTICULAR-COURSE J... 2016-05-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-003490-26 A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE IDIO... 2017-06-15 bad-data
Ongoing, reported early 2012-003554-83 A double-blind, placebo-controlled, randomized, multicenter phase III study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-posi... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-004455-36 AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT 2017-09-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-004879-38 A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE III NEOADJUVANT STUDY EVALUATING TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB COMPARED WITH CHEMOTHERAPY PLUS TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WIT... 2018-05-29 bad-data
Other 2012-004902-82 A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINE... not-yet-due
Reported results 2012-005776-34 A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-R... 2016-08-17 due-trials
Reported results 2013-000054-22 OPEN-LABEL, PHASE IIIB STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS TOCILIZUMAB (MONOTHERAPY OR COMBINATION THERAPY WITH METHOTREXATE OR OTHER DMARDS) IN PATIENTS WITH ACTIVE RHEUMATOID A... 2016-08-04 due-trials
Ongoing, reported early 2013-000087-29 A multicenter, open-label, single-arm, phase IIIb, international study evaluating the safety of Obinutuzumab alone or in combination with chemotherapy in patients with previously untreated or relapsed... not-yet-due
Ongoing, reported early 2013-000123-13 A single arm multi-center study investigating the at home administration of trastuzumab subcutaneous vial for the treatment of patients with HER2-positive early breast cancer not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-000175-33 A Phase III, randomized, double-blind, placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second c... 2016-12-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-000176-15 A Phase III, randomized, double-blind, placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second c... 2017-01-03 bad-data
Completed, but no date, and reported results 2013-000342-19 MULTI-CENTER, OPEN LABEL, SINGLE ARM PHASE IIIB STUDY ON SAFETY AND EFFICACY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) IN MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGIC DISEA... bad-data
Reported results 2013-000359-42 Multicenter, open label, phase IIIb study to evaluate the safety and tolerability of subcutaneous tocilizumab as monotherapy and/or in combination with methotrexate or other non-biologic disease modif... 2016-07-11 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-000568-28 A phase II randomized, double-blind study of neoadjuvant letrozole plus GDC-0032 versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer 2017-03-13 bad-data
Ongoing 2013-000647-12 A single arm, multicentre, phase IIIb study to evaluate safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab administered during induction phase or maintenance in previously untr... not-yet-due
Ongoing 2013-000829-31 A LOCAL, OPEN LABEL, MULTICENTRE, PHASE IIIB STUDY, INVESTIGATING SUBCUTANEOUS TRASTUZUMAB ADMINISTERED AT HOME WITH SINGLE INJECTION DEVICE IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-000868-29 A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST LINE TREATMENT FOR PATIENTS WITH M... 2015-04-15 bad-data
Reported results 2013-000900-41 A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED 2014-04-28 due-trials
Other 2013-001023-39 LISAH: AN OPEN-LABEL, RANDOMISED PHASE II STUDY ASSESSING QUALITY OF LIFE ASSOCIATED WITH SUBCUTANEOUS TRASTUZUMAB INJECTED INTO THE THIGH OR UPPER ARM IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANC... not-yet-due
Completed, but no date, and reported results 2013-001118-14 Ensayo Clínico Fase IIIb abierto no-controlado para evaluar la seguridad del cambio de rituximab intravenoso a rituximab subcutáneo durante el tratamiento de primera línea de Linfoma No-Hodgkin Folicu... bad-data
Listed as ongoing, but also has a completion date 2013-001141-14 A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE 2015-04-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-001142-34 A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER A... 2017-12-05 bad-data
Ongoing, reported early 2013-001161-16 NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCALLY ... not-yet-due
Listed as ongoing, but also has a completion date 2013-001163-24 A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. 2017-11-06 bad-data
Reported results 2013-001263-23 A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS) 2016-05-06 due-trials
Ongoing, reported early 2013-001569-17 A national, open-label, single-arm, phase IIIB study to evaluate the efficacy of weekly tocilizumab subcutaneous, administered as monotherapy or in combination with methotrexate and/or other DMARDS in... not-yet-due
Reported results 2013-001570-14 A phase IB/II study to evaluate the safety and efficacy of vismodegib in relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS). 2014-11-03 due-trials
Reported results 2013-002007-34 Tocilizumab SC in patients with active rheumatoid arthritis and inadequate response to DMARDs. A single-arm, open-label study to evaluate safety, tolerability and efficacy. In a sub-group of patients ... 2016-09-13 due-trials
Completed, but no date, and reported results 2013-002150-79 TOSCARA: An open-label, single-arm study to evaluate the efficacy, safety and tolerability of tocilizumab (TCZ) subcutaneous in TCZ-naïve patients with active rheumatoid arthritis bad-data
Reported results 2013-002341-11 A SINGLE BLIND PHASE IV PHARMACODYNAMIC STUDY TO EVALUATE NEUTROPHIL DISTRIBUTION KINETICS AND FUNCTION FOLLOWING SINGLE-DOSE TOCILIZUMAB TREATMENT IN HEALTHY SUBJECTS 2014-12-10 due-trials
Reported results 2013-002429-52 A PHASE IIIb STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) GIVEN AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGICS DMARDs... 2016-03-09 due-trials
Ongoing, reported early 2013-003167-58 A PHASE II, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL not-yet-due
Ongoing, reported early 2013-003330-32 A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER not-yet-due
Ongoing, reported early 2013-003331-30 A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER ... not-yet-due
Ongoing 2013-003388-79 PHASE II TRIAL TO EVALUATE THE EFFICACY OF OBINUTUZUMAB (RO5072759) + BENDAMUSTINE TREATMENT IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA not-yet-due
Listed as ongoing, but also has a completion date 2013-003390-95 A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s disease 2017-08-31 bad-data
Ongoing, reported early 2013-003749-40 A Phase Ib/II, open label study evaluating the safery and pharmacokinetics of GDC-0199 (ABT-199) in combination with Rituximab (R) or Obinutuzumab (G) plus cyclophosphamide, doxorubicin, vincristine, ... not-yet-due
Ongoing, reported early 2013-004133-33 RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER not-yet-due
Ongoing 2013-004277-27 PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEBO... not-yet-due
Ongoing 2013-004278-88 PHASE III, DOUBLE BLIND, PLACEBO-CONTROLLED, not-yet-due
Ongoing 2013-004279-11 PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEB... not-yet-due
Ongoing 2013-004280-31 PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (MAINTENANCE OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH PLACEBO IN PATIENTS WITH MODERATE... not-yet-due
Ongoing 2013-004282-14 PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE CO... not-yet-due
Ongoing 2013-004435-72 AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES not-yet-due
Reported results 2013-004625-81 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA. 2016-01-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-005108-32 A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO5520985 PLUS FOLFOX VERSUS BEVACIZUMAB PLUS FOLFOX IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COL... 2017-02-01 bad-data
Other 2013-005212-98 LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS not-yet-due
Ongoing, reported early 2013-005486-39 A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL not-yet-due
Reported results 2014-000049-56 A phase II, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately... 2016-04-18 due-trials
Listed as ongoing, but also has a completion date 2014-000106-35 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY T... 2018-01-23 bad-data
Listed as ongoing, but also has a completion date 2014-000107-27 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY T... 2018-01-29 bad-data
Ongoing, reported early 2014-000156-28 A MULTICENTER, MULTINATIONAL, PHASE II STUDY TO EVALUATE PERJETA® IN COMBINATION WITH HERCEPTIN® AND STANDARD NEOADJUVANT ANTHRACYCLINE-BASED CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE, LOCALLY ADVAN... not-yet-due
Reported results 2014-000275-14 A Phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhaled ... 2016-10-13 due-trials
Ongoing 2014-000382-41 A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris not-yet-due
Not reported 2014-000963-42 A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of oral vismodegib for the treatment of idiopathic pulmonary fibrosis 2015-07-17 due-trials
Other 2014-001017-61 A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL) not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-001237-83 A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2 IHC-POSITIVE, LOCALLY ADVANCED OR METASTATIC NON−SMALL CELL LUNG CANCER WHO HAVE RECEIVED AT LEAST ONE PRIOR CH... 2018-07-26 bad-data
Ongoing 2014-001361-28 A Phase Ib/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (DCDS4501A) in combination with rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relaps... not-yet-due
Ongoing 2014-001458-40 A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN® SC IN COMBINATION WITH PERJETA® AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2−POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-001498-15 OPEN-LABEL PHASE Ib/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HISTOLO... 2016-03-14 bad-data
Ongoing 2014-001810-24 A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND GDC-0199 (ABT-199) VERSUS OBINUTUZUMAB AND CHLORAMBUCIL ... not-yet-due
Ongoing 2014-002048-42 An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-la R... not-yet-due
Ongoing 2014-002230-32 A MULTISTAGE, PHASE II, STUDY EVALUATING not-yet-due
Completed, reported early 2014-002246-41 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6885247 FOLLOWING 12 WEEKS OF TREA... 2016-12-15 not-yet-due
Other 2014-002835-32 AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE IB STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST) IN COMBINATION WITH MPDL3... not-yet-due
Ongoing 2014-003065-15 A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY ... not-yet-due
Ongoing 2014-003083-21 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH A PLATINUM AGENT (CISPLATIN OR CARBOPLATIN) IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1... not-yet-due
Completed, report not yet due 2014-003106-33 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH GEMCITABINE+ CISPLATIN OR CARBOPLATIN FOR PD-L1−SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMO... 2017-12-07 not-yet-due
Ongoing 2014-003185-25 A PHASE III, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE AND HER2 NEGATIVE ... not-yet-due
Ongoing 2014-003205-15 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAP... not-yet-due
Ongoing 2014-003206-32 A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+NAB-PACLITAXEL FOR CHEMOTHERA... not-yet-due
Ongoing 2014-003207-30 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN+PACLITAXEL+B... not-yet-due
Ongoing 2014-003208-59 A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+PACLITAXEL OR ATEZOLIZUMAB IN... not-yet-due
Ongoing, reported early 2014-003231-19 A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR META... not-yet-due
Ongoing 2014-003824-36 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY T... not-yet-due
Ongoing 2014-003855-76 AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 not-yet-due
Completed, report not yet due 2014-004673-16 Prospective, multicentre, placebo-controlled, double-blind study to compare the efficacy of maintenance treatment with tocilizumab with or without glucocorticoid discontinuation in rheumatoid arthrit... 2018-02-20 not-yet-due
Ongoing 2014-004684-20 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF Atezolizumab (Anti-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA not-yet-due
Ongoing 2014-004685-25 A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF COBIMETINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS not-yet-due
Listed as ongoing, but also has a completion date 2014-004697-41 AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI−PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS 2017-06-28 bad-data
Listed as ongoing, but also has a completion date 2014-005438-69 AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF ONARTUZUMAB IN PATIENTS WITH SOLID TUMORS ON STUDY TREATMENT PREVIOUSLY ENROLLED IN AN F. HOFFMANN-LA ROCHE- AND/OR GENENTECH-SPONSORED STUDY 2018-06-29 bad-data
Ongoing 2014-005490-37 A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREV... not-yet-due
Ongoing 2014-005491-28 A MULTICENTRE OPEN-LABEL SINGLE-ARM PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC, RECURRENT OR PERSISTENT... not-yet-due
Ongoing 2014-005603-25 A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA AFTE... not-yet-due
Ongoing 2015-000269-30 AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS not-yet-due
Ongoing 2015-000424-28 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS not-yet-due
Listed as ongoing, but also has a completion date and reported results 2015-000435-33 A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA) 2017-07-13 bad-data
Ongoing, reported early 2015-000634-29 RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS PEMETREXED OR DOCETAXEL IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREATED ... not-yet-due
Reported results 2015-001122-42 A Phase II, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with chronic obstructive pulmonary disease and a history of exacerbations 2017-02-17 due-trials
Completed, report not yet due 2015-001377-40 PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS. 2018-04-10 not-yet-due
Other 2015-001589-25 Multicenter, open-label, single arm study to evaluate long-term safety, tolerability, and effectiveness of 10mg/kg BID olesoxime in patients with Spinal Muscular Atrophy not-yet-due
Completed, but no date, and reported results 2015-001620-33 A Phase Ib/III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of vismodegib in combination with ruxolitinib versus placebo and ruxolitinib in patients with int... bad-data
Ongoing 2015-001731-20 A SINGLE ARM, OPEN LABEL, PHASE II, MULTICENTER STUDY TO ASSESS THE DETECTION OF THE BRAF V600 MUTATION ON cfDNA FROM PLASMA IN PATIENTS WITH ADVANCED MELANOMA not-yet-due
Ongoing 2015-001999-22 A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CE... not-yet-due
Ongoing 2015-002022-39 A randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of Obinutuzumab in patients with ISN/RPS 2003 class III or IV Lupus Nephritis not-yet-due
Ongoing 2015-002100-83 A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RITUXIMAB IN COMB... not-yet-due
Ongoing 2015-002467-42 A phase Ib/II study evaluating the safety and efficacy of Atezolizumab in combination with obinutuzumab plus lenalidomide in patients with relapsed or refractory follicular lymphoma not-yet-due
Listed as ongoing, but also has a completion date and reported results 2015-002866-21 A RANDOMIZED, MULTICENTER, OPEN-LABEL, 2018-05-03 bad-data
Ongoing 2015-003034-27 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODOMAL-TO-MILD ALZHEIMER’S DISEASE not-yet-due
Completed, report not yet due 2015-003227-66 A randomized, double-blind, placebo-controlled, parallel group, safety, efficacy and pharmacodynamic study of basmisanil (RO5186582) in adults with severe motor impairment following an ischemic stroke... 2017-12-12 not-yet-due
Reported results 2015-003280-11 AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS 2017-05-16 due-trials
Ongoing 2015-003386-28 A phase Ib/II multi-arm study with venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients ≥ 60 years with relapsed or refractory acute myeloid leukemia ... not-yet-due
No trial status on register 2015-003537-99 A PHASE IV MULTICENTER, RANDOMIZED, OPEN LABEL, TWO-PERIOD CROSSOVER STUDY IN PATIENTS WITH CYSTIC FIBROSIS TO EVALUATE THE COMPARABLE EFFICACY AND SAFETY OF PULMOZYME® DELIVERED BY THE ERAPID™ NEBULI... bad-data
Ongoing 2015-003605-42 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN+PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN+PEMETREXED IN ... not-yet-due
Ongoing 2015-004105-16 A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAÏVE ADVANCED OR RECURRENT (STAGE I... not-yet-due
Ongoing 2015-004189-27 A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH... not-yet-due
No trial status on register 2015-004211-20 A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma bad-data
Listed as ongoing, but also has a completion date and reported results 2015-004476-30 A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME 2017-07-10 bad-data
Other 2015-004845-25 A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and rituxim... not-yet-due
Ongoing 2015-004861-97 A PHASE I/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTIPD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL ... not-yet-due
Ongoing 2015-005131-40 A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC ... not-yet-due
Ongoing 2015-005597-38 An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying... not-yet-due
Other 2016-000072-17 A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT... not-yet-due
Other 2016-000073-21 A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRI... not-yet-due
Ongoing 2016-000202-11 A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with ... not-yet-due
Ongoing 2016-000250-35 A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN not-yet-due
No trial status on register 2016-000263-17 Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection bad-data
Listed as ongoing, but also has a completion date 2016-000423-13 A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE C... 2018-01-31 bad-data
Ongoing 2016-000750-35 A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND... not-yet-due
No trial status on register 2016-000758-37 A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas bad-data
Ongoing 2016-000778-40 A TWO PART SEAMLESS, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN INFANTS WITH TYPE1 SPINAL MUSCULAR ATROPHY not-yet-due
No trial status on register 2016-001001-16 A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Persistency of Response with or without Xolair after Long-Term Therapy (XPORT) bad-data
No trial status on register 2016-001008-49 A randomized, multicenter trial of oseltamivir doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days in influenza patients with pandemic (H1N1) 2009 bad-data
No trial status on register 2016-001042-25 A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation bad-data
No trial status on register 2016-001043-39 An Open-Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose Vs Concentration Controlled Cellcept Regimens For Patients Following A Single Organ Renal Transplantation In... bad-data
No trial status on register 2016-001044-18 A phase IIIb, openlabel, comparative, randomized study on resistance of Influenza A/H1N1 2009 virus to treatment with Oseltamivir at standard dose versus double dose bad-data
No trial status on register 2016-001045-12 A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas. bad-data
No trial status on register 2016-001046-26 Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents with Advanced Solid Tumors bad-data
Other 2016-001094-33 A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS (Q4W) IN PATIENTS WITH HEMOPHILIA A not-yet-due
No trial status on register 2016-001160-11 An Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Tacrolimus Ointment in the Treatment of Atopic Dermatitis in Pediatric Patients bad-data
Other 2016-001654-18 A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy not-yet-due
No trial status on register 2016-001661-91 Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents bad-data
Ongoing 2016-001881-27 A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing ... not-yet-due
Ongoing 2016-002126-36 A randomized, double-blind, placebo-controlled, multi-center phase II study to evaluate the safety and efficacy of RO7123520 as adjunct treatment in patients with moderately to severely active rheumat... not-yet-due
Ongoing 2016-002128-10 An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) not-yet-due
Ongoing 2016-002480-34 A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RI... not-yet-due
Ongoing 2016-002482-54 A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTA... not-yet-due
Ongoing 2016-002625-11 AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT not-yet-due
Ongoing 2016-002744-17 MULTICENTER, INTERNATIONAL, DOUBLEBLIND, TWO-ARM, RANDOMIZED, PLACEBO CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD not-yet-due
Ongoing 2016-002937-31 An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis not-yet-due
No trial status on register 2016-003003-54 An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection bad-data
No trial status on register 2016-003004-31 An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection bad-data
Ongoing 2016-003092-22 A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CA... not-yet-due
No trial status on register 2016-003201-34 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis bad-data
No trial status on register 2016-003260-39 Intravenous Granisetron (Kytril) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy bad-data
Ongoing 2016-003288-20 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE not-yet-due
Ongoing 2016-003472-52 A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE ... not-yet-due
Ongoing 2016-003579-22 A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOM... not-yet-due
Ongoing 2016-003695-47 A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) not-yet-due
Ongoing 2016-003924-22 AN OPEN-LABEL, MULTICENTER, SINGLE-ARM, PHASE II STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALECTINIB IN PATIENTS WITH ALK-REARRANGED NON−SMALL CELL LUNG CANCER AFTER DISEASE PROGRESSION ON PRIOR ALK ... not-yet-due
Ongoing 2016-004024-29 A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WIT... not-yet-due
Ongoing 2016-004126-42 A PHASE Ib/II, OPEN-LABEL, MULTICENTER,RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL... not-yet-due
Ongoing 2016-004184-39 AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY not-yet-due
Ongoing 2016-004366-25 A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS not-yet-due
Ongoing 2016-004387-18 A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVAN... not-yet-due
Ongoing 2016-004429-17 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PRE... not-yet-due
Ongoing 2016-004529-17 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESECTA... not-yet-due
Ongoing 2016-004734-22 A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WITH ... not-yet-due
Other 2016-004779-39 AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASCERTAIN THE OPTIMAL STARTING DOSE OF MIRCERA® GIVEN SUBCUTANEOUSLY FOR THE MAINTENANCE TREATMENT OF ANEMIA IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY D... not-yet-due
Ongoing 2016-005119-42 A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOCALL... not-yet-due
Ongoing 2016-005189-75 AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY not-yet-due
Ongoing 2017-000076-28 A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) HARBORING A... not-yet-due
Ongoing 2017-000087-15 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED ... not-yet-due
Ongoing 2017-000207-24 A MULTICENTER, INTERNATIONAL, ROLLOVER STUDY OF ALECTINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE OR REARRANGED DURING TRANSFECTION (RET)-POSITIVE CANCER not-yet-due
Ongoing 2017-000794-37 A PHASE II, OPEN-LABEL, MULTICENTER, MULTI-COHORT STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH SOLID TUMORS not-yet-due
Ongoing 2017-000830-68 A PHASE IB/II STUDY OF COBIMETINIB ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH VENETOCLAX, WITH OR WITHOUT ATEZOLIZUMAB, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA not-yet-due
Ongoing 2017-001267-21 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NONSMALL CELL L... not-yet-due
Ongoing 2017-001313-93 AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS not-yet-due
Ongoing 2017-001364-38 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE not-yet-due
Ongoing 2017-001365-24 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER’S DISEASE not-yet-due
Ongoing 2017-001409-34 A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL... not-yet-due
Ongoing 2017-001548-36 A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, ... not-yet-due
Ongoing 2017-001718-28 A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS not-yet-due
Ongoing 2017-001724-22 A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS not-yet-due
Ongoing 2017-001764-37 A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LU... not-yet-due
Ongoing 2017-001800-31 A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE not-yet-due
Ongoing 2017-002023-21 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND... not-yet-due
Ongoing 2017-002038-21 A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE ... not-yet-due
Ongoing 2017-002350-36 A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND ... not-yet-due
Ongoing 2017-002702-12 A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE III STUDIES (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER’S DISEASE not-yet-due
Ongoing 2017-002857-12 A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN P... not-yet-due
Ongoing 2017-003040-20 A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemothera... not-yet-due
Ongoing 2017-003182-94 AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (... not-yet-due
Ongoing 2017-003302-40 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCALLY... not-yet-due
Ongoing 2017-003450-16 OPEN-LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS not-yet-due
Other 2017-003649-10 A PHASE I, OPEN–LABEL, RANDOMIZED, PHARMACOKINETIC, PHARMACODYNAMIC, AND SAFETY STUDY OF ETROLIZUMAB FOLLOWED BY OPEN–LABEL EXTENSION AND SAFETY MONITORING IN PEDIATRIC PATIENTS FROM 4 YEARS TO LESS T... not-yet-due
Ongoing 2017-003691-31 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN not-yet-due
Ongoing 2017-004331-37 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ≥ ... not-yet-due
Ongoing 2017-004886-29 A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED... not-yet-due
Ongoing 2017-004897-32 A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and tr... not-yet-due
Ongoing 2018-000280-81 A PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF MTIG7192A, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-... not-yet-due
Ongoing 2018-000759-41 A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZUMAB ... not-yet-due